文献速递糖尿病

甘精胰岛素U300与U100在1型糖尿病稳态下的药代/药效及肝糖生成调节

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2018-10-10

本研究在18例1型糖尿病患者中,经3个月甘精胰岛素U300或U100个体化剂量滴定至空腹血糖正常后,用正常血糖钳夹技术比较稳态下药代动力学、药效学及内源性肝糖生成。两种制剂24小时总体降糖效力相当,但U300在给药后前6小时暴露和效应较低、后12小时较高,且日内变异性更小。U300对肝糖生成的抑制模式更接近生理。

要点

  • 个体化临床剂量下U300与U100的24小时总体降糖效力相当
  • U300前6小时作用减弱、后12小时增强,日内变异性更低
  • U300对肝糖生成的调节更接近生理模式

核心结论

  • 个体化临床剂量的甘精胰岛素U300与U100在1型糖尿病稳态下具有相似的24小时正常血糖潜力。
  • 甘精胰岛素U300较U100表现出更稳定的作用曲线,日内变异性更低,且对肝糖生成的调节更接近生理。

研究设计与样本

  • 随机交叉研究,纳入18例1型糖尿病患者(年龄40±12岁,病程26±12年,BMI 23.4±2 kg/m2,A1C 7.19±0.52% [55±5.7 mmol·mol-1])。
  • 受试者分别接受甘精胰岛素U300或U100晚间给药3个月,剂量滴定至空腹血糖正常,采用个体化剂量(U300 0.35±0.08 U/kg,U100 0.28±0.07 U/kg)进行正常血糖钳夹。

主要发现

  • 24小时血浆游离胰岛素浓度曲线下面积等效(点估计1.11 [90% CI 1.03; 1.20]),但U300前6小时较低(0.91 [90% CI 0.86; 0.97]),后12小时较高(1.38 [90% CI 1.21; 1.56])。
  • 两种制剂均维持24小时正常血糖(0.99 [90% CI 0.98; 1.0]),葡萄糖输注率24小时总体等效(1.03 [90% CI 0.88; 1.21]),但U300前12小时较低(0.77 [90% CI 0.62; 0.95]),后12小时较高(1.53 [90% CI 1.23; 1.92])。
  • U300在0-6小时对肝糖生成的抑制较弱,而在18-24小时抑制较强。
  • U300的日内药代动力学和药效学变异性(波动)分别较U100低50%和17%。

临床怎么用

  • 在1型糖尿病个体化临床剂量下,U300与U100总体降糖效力相当,但U300作用更平稳、变异性更小。
  • U300前6小时作用较弱、后12小时作用较强,调整剂量或评估血糖时需考虑其时间分布特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study characterized the pharmacokinetics (PK), pharmacodynamics (PD), and endogenous (hepatic) glucose production (EGP) of clinical doses of glargine U300 (Gla-300) and glargine U100 (Gla-100) under steady-state (SS) conditions in type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: T1DM subjects (N = 18, age 40 ± 12 years, T1DM duration 26 ± 12 years, BMI 23.4 ± 2 kg/m2, A1C 7.19 ± 0.52% [55 ± 5.7 mmol · mol-1-1]) were studied after 3 months of Gla-300 or Gla-100 (evening dosing) titrated to fasting euglycemia (random, crossover) with the euglycemic clamp using individualized doses (Gla-300 0.35 ± 0.08, Gla-100 0.28 ± 0.07 units · kg-1). RESULTS: Plasma free insulin concentrations (free immunoreactive insulin area under the curve) were equivalent over 24 h with Gla-300 versus Gla-100 (point estimate 1.11 [90% CI 1.03; 1.20]) but were reduced in the first 6 h (0.91 [90% CI 0.86; 0.97]) and higher in the last 12 h postdosing (1.38 [90% CI 1.21; 1.56]). Gla-300 and Gla-100 both maintained 24 h euglycemia (0.99 [90% CI 0.98; 1.0]). The glucose infusion rate was equivalent over 24 h (1.03 [90% CI 0.88; 1.21]) but was lower in first (0.77 [90% CI 0.62; 0.95]) and higher (1.53 [90% CI 1.23; 1.92]) in the second 12 h with Gla-300 versus Gla-100. EGP was less suppressed during 0-6 h but more during 18-24 h with Gla-300. PK and PD within-day variability (fluctuation) was 50% and 17% lower with Gla-300. CONCLUSIONS: Individualized, clinical doses of Gla-300 and Gla-100 resulted in a similar euglycemic potential under SS conditions. However, Gla-300 exhibited a more stable profile, with lower variability and more physiological modulation of EGP compared with Gla-100.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Porcellati F, Lucidi P, Candeloro P, et al. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes. Diabetes Care. 2018. PMID: 30305345. doi:10.2337/dc18-0706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。